Photocure Cash Flow Conversion Efficiency
Photocure cash flow conversion efficiency. Based on the latest financial reports, Photocure (PHO) has a cash flow conversion efficiency ratio of 0.103x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr62.78 Million ≈ $6.61 Million USD) by net assets (Nkr606.75 Million ≈ $63.85 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Photocure (2002–2025)
Cash flow conversion efficiency of Photocure from 2002 to 2025. This chart illustrates how Photocure's cash flow conversion efficiency has evolved over time, based on yearly financial data. View PHO share price today for real-time trading data and today's change.
Photocure Cash Flow Conversion Ratio Explained
Photocure cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Photocure Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Photocure ranked by their cash flow conversion efficiency. Also see market value of Photocure for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Varia US Properties Ltd
SW:VARN
|
0.018x |
|
Rawlplug S.A.
WAR:RWL
|
0.070x |
|
Lan Fa Textile Co Ltd
TW:1459
|
0.028x |
|
Forrester Research Inc
NASDAQ:FORR
|
-0.030x |
|
Bank Artha Graha Internasional
JK:INPC
|
0.010x |
|
Bukaka Teknik Utama Tbk Pt
JK:BUKK
|
0.033x |
|
Fate Therapeutics Inc
NASDAQ:FATE
|
-0.104x |
|
Astec LifeSciences Limited
NSE:ASTEC
|
-0.020x |
Annual Cash Flow Conversion Efficiency for Photocure (2002–2025)
The table below shows the annual cash flow conversion efficiency of Photocure from 2002 to 2025. Review Photocure (PHO) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Nkr484.23 Million ≈ $50.96 Million |
Nkr25.96 Million ≈ $2.73 Million |
0.054x | -64.96% |
| 2024-12-31 | Nkr501.72 Million ≈ $52.79 Million |
Nkr76.75 Million ≈ $8.08 Million |
0.153x | +151.36% |
| 2023-12-31 | Nkr482.85 Million ≈ $50.81 Million |
Nkr29.39 Million ≈ $3.09 Million |
0.061x | +1495.53% |
| 2022-12-31 | Nkr462.73 Million ≈ $48.69 Million |
Nkr-2.02 Million ≈ $-212.35K |
-0.004x | -109.18% |
| 2021-12-31 | Nkr502.63 Million ≈ $52.89 Million |
Nkr23.89 Million ≈ $2.51 Million |
0.048x | +54.94% |
| 2020-12-31 | Nkr508.13 Million ≈ $53.47 Million |
Nkr15.59 Million ≈ $1.64 Million |
0.031x | -69.03% |
| 2019-12-31 | Nkr208.59 Million ≈ $21.95 Million |
Nkr20.66 Million ≈ $2.17 Million |
0.099x | +172.38% |
| 2018-12-31 | Nkr176.34 Million ≈ $18.56 Million |
Nkr-24.12 Million ≈ $-2.54 Million |
-0.137x | -26.45% |
| 2017-12-31 | Nkr218.08 Million ≈ $22.95 Million |
Nkr-23.59 Million ≈ $-2.48 Million |
-0.108x | -242.01% |
| 2016-12-31 | Nkr251.94 Million ≈ $26.51 Million |
Nkr19.19 Million ≈ $2.02 Million |
0.076x | +176.09% |
| 2015-12-31 | Nkr210.06 Million ≈ $22.10 Million |
Nkr-21.03 Million ≈ $-2.21 Million |
-0.100x | -294.80% |
| 2014-12-31 | Nkr240.06 Million ≈ $25.26 Million |
Nkr-6.09 Million ≈ $-640.63K |
-0.025x | +93.16% |
| 2013-12-31 | Nkr269.12 Million ≈ $28.32 Million |
Nkr-99.72 Million ≈ $-10.49 Million |
-0.371x | -156.53% |
| 2012-12-31 | Nkr380.27 Million ≈ $40.02 Million |
Nkr-54.93 Million ≈ $-5.78 Million |
-0.144x | -84.12% |
| 2011-12-31 | Nkr439.34 Million ≈ $46.23 Million |
Nkr-34.47 Million ≈ $-3.63 Million |
-0.078x | -330.80% |
| 2010-12-31 | Nkr458.85 Million ≈ $48.28 Million |
Nkr15.60 Million ≈ $1.64 Million |
0.034x | -95.55% |
| 2009-12-31 | Nkr415.78 Million ≈ $43.75 Million |
Nkr317.44 Million ≈ $33.40 Million |
0.763x | +355.48% |
| 2008-12-31 | Nkr199.69 Million ≈ $21.01 Million |
Nkr-59.68 Million ≈ $-6.28 Million |
-0.299x | +18.77% |
| 2007-12-31 | Nkr259.99 Million ≈ $27.36 Million |
Nkr-95.66 Million ≈ $-10.07 Million |
-0.368x | -281.35% |
| 2006-12-31 | Nkr326.94 Million ≈ $34.40 Million |
Nkr66.33 Million ≈ $6.98 Million |
0.203x | +113.94% |
| 2005-12-31 | Nkr48.47 Million ≈ $5.10 Million |
Nkr-70.54 Million ≈ $-7.42 Million |
-1.455x | -147.85% |
| 2004-12-31 | Nkr85.57 Million ≈ $9.00 Million |
Nkr-50.25 Million ≈ $-5.29 Million |
-0.587x | -9.86% |
| 2003-12-31 | Nkr131.90 Million ≈ $13.88 Million |
Nkr-70.51 Million ≈ $-7.42 Million |
-0.535x | -75.36% |
| 2002-12-31 | Nkr167.00 Million ≈ $17.57 Million |
Nkr-50.91 Million ≈ $-5.36 Million |
-0.305x | -- |
About Photocure
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through two segments, Commercial Franchise and Development Portfolio. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It is also developing Cevira, a photodynamic drug-device combination pro… Read more